公司资料
Delcath Systems 股价、新闻与催化剂
- 股票代码:
- DCTH
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
17.05 USD (+1.91%)
收盘价
最后更新: 2026年8月17日
364M USD
市值
股价为何变动
As of Aug 17, 2026, DCTH closed up 1.91% at $17.05. No new same-company headline was identified in the current news window.
公司概览
Interventional Oncology
Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure.
HEPZATO KIT
HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is approved in the United States for selected adults with unresectable hepatic-dominant metastatic uveal melanoma. CHEMOSAT is the European commercial version of Delcath's hepatic-delivery platform. The company supports adoption through treatment-center activation, clinician training and procedure-based consumable sales.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。